Assessing and treating cancer

Patent metadata

Field	Value
Publication number	US-11243207-B2
Application number	US-201916368477-A
Country	US
Kind code	B2
Filing date	Mar 28, 2019
Priority date	Mar 29, 2018
Publication date	Feb 8, 2022
Grant date	Feb 8, 2022

Abstract

This document relates to methods and materials for identifying and/or treating mammals having cancer (e.g., a SCD1-associated cancer). For example, methods and materials for using one or more stearoyl CoA desaturase 1 (SCD1) polypeptide inhibitors to treat a mammal having cancer (e.g., a SCD1-associated cancer) are provided.

First claim

What is claimed is:

1. A method for identifying and treating a mammal having a cancer exhibiting stearoyl-Coenzyme A desaturase 1 (SCD1) polypeptide expression that is responsive to treatment with a SCD1 polypeptide inhibitor, said method comprising:
detecting an elevated level of cMyc polypeptides within a biological sample of cancer from said mammal, thereby identifying said cancer as being responsive to treatment with said SCD1 polypeptide inhibitor, and
administering said SCD1 polypeptide inhibitor to said mammal, wherein said SCD1 polypeptide inhibitor is a compound having Formula (II) or Formula (IIa):

or pharmaceutically acceptable salt thereof;
wherein:
R 1 is halo;
X is (C═O)NR 4 —;
Y is

and
R 2 , R 3 , and R 4 are each independently H or an unsubstituted C 1-6 alkyl.

2. The method of claim 1 , wherein said SCD1 polypeptide inhibitor is SSI-4, 2-{[4-(2-Chlorophenoxy)piperidine-1-carbonyl]amino}-N-methylpyridine-4-carboxamide:

or pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein said method comprises detecting SCD1 polypeptide expression within said biological sample.

4. The method of claim 1 , wherein said mammal is a human.

5. The method of claim 1 , wherein said cancer is selected from the group consisting of liver cancer, renal cell carcinoma, ovarian cancer, breast cancer, prostate cancer, colon cancer, pancreatic cancer, bladder cancer, lung cancer, thyroid cancer, brain cancer, melanoma, and lymphoma.

6. The method of claim 5 , wherein said cancer is a liver cancer.

7. The method of claim 6 , wherein said liver cancer is a hepatocellular carcinoma.

8. The method of claim 6 , wherein said liver cancer is a cholangiocarcinoma.

9. The method of claim 1 , further comprising detecting an elevated level of survivin polypeptides within said biological sample from said mammal.

10. The method of claim 1 , wherein said method further comprises administering an additional therapeutic agent used to treat cancer to said mammal.

11. The method of claim 10 , wherein said additional therapeutic agent is a chemotherapeutic agent.

12. The method of claim 11 , wherein said chemotherapeutic agent is a kinase inhibitor.

13. The method of claim 12 , wherein said kinase inhibitor is selected from the group consisting of sorafenib, regorafenib, bortezomib, erlotinib, gefitinib, imatinib, vemurafenib, and vismodegib.

14. The method of claim 13 , wherein said kinase inhibitor is sorafenib.

Assignees

• Mayo Found Medical Education & Res

Inventors

• Copland Iii John A
• Marlow Laura Ann

Classifications

• G01N33/5758

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• G01N33/57525 Primary

  of the liver or pancreas · CPC title

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• A61K31/4412 Primary

  having oxo groups directly attached to the heterocyclic ring · CPC title

• A61P35/00

  Antineoplastic agents · CPC title